{
  "num_tested_probands": [
    3,
    0
  ],
  "num_positive_het_probands": [
    0,
    0
  ],
  "positive_phenotypes": [
    "prolonged duration of action of succinylcholine",
    []
  ],
  "num_compound_or_double_hets": [
    1,
    3,
    0
  ],
  "explanation": {
    "num_tested_probands": [
      "The number of individual probands for whom genetic testing was reported. In this case, three patients were referred to the DCRU because of prolonged duration of action of succinylcholine.",
      "No probands were tested in these reports."
    ],
    "num_positive_het_probands": [
      "The number of probands who were heterozygous for a pathogenic variant. In this case, none of the tested probands were found to be heterozygous for a pathogenic variant.",
      "No heterozygous probands were identified in these reports."
    ],
    "positive_phenotypes": [
      "Clinical phenotypes associated with the positive probands. In this case, one patient was found to have prolonged duration of action of succinylcholine.",
      "No clinical phenotypes were mentioned in these reports."
    ],
    "num_compound_or_double_hets": [
      "The number of individuals reported to have compound or double heterozygous mutations. In this case, one patient was found to be compound heterozygous for BCHE*328D and BCHE*142M.",
      "No compound or double heterozygotes were reported in these articles."
    ],
    "BCHE*115D*I3E4-14C": [
      "a known silent mutation"
    ],
    "BCHE*FS126": [
      "deletion of two nucleotides (376\u2013377) resulting in a shift in the translational reading frame and a truncated protein"
    ],
    "BCHE*328D": [
      "nucleotide substitution at position 983 leading to an amino acid substitution of alanine by aspartate"
    ]
  }
}